Free Research Reports on These Biotech Stocks -- Spectrum Pharma, Teligent, Vertex Pharma, and VIVUS

Wednesday, January 17, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Jan. 17, 2018 /PRNewswire/ -- strives to bring the best free research to the investment community. 

Today we are offering reports on SPPI, TLGT, VRTX, and VVUS which can be accessed for free by signing up to 24/7 Wall St. reported that the iShares Nasdaq Biotech ETF was only up about 21% in 2017, just slightly
above the S&P 500. However, the report added, Merrill Lynch believes that this could be the year biotechs break out. In 2018, the firm believes that the need for growth, positive impact from tax reform, and a boost in M&A can drive sector outperformance. Pre-market today, assesses the following industry players: Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI), Teligent Inc. (NASDAQ: TLGT), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), and VIVUS Inc. (NASDAQ: VVUS). All you have to do is sign up today for this free limited time offer by clicking the link below.

Spectrum Pharmaceuticals

Henderson, Nevada headquartered Spectrum Pharmaceuticals Inc.'s stock finished Tuesday's session 2.16% lower at $19.00 with a total trading volume of 938,672 shares. Over the previous three months and the past year, the Company's shares have surged 42.22% and 308.60%, respectively. The stock is trading above its 50-day and 200-day moving averages by 0.43% and 64.92%, respectively. Moreover, shares of Spectrum Pharma, which develops and commercializes oncology and hematology drug products, have a Relative Strength Index (RSI) of 52.45.

On December 18th, 2017, research firm B. Riley FBR, Inc. initiated a 'Buy' rating on the Company's stock, with a target price of $26 per share. Get the full research report on SPPI for free by clicking below at:


Shares in Buena, New Jersey-based Teligent Inc. plummeted 5.03%, ending yesterday's session at $3.40. A total volume of 1.14 million shares was traded, which was above their three months average volume of 703,640 shares. The stock is trading 11.01% below its 50-day moving average. Moreover, shares of Teligent, which develops, manufactures, and markets topical formulations in the US, have an RSI of 37.66. Find your free research report TLGT at:

Vertex Pharmaceuticals

On Tuesday, Boston, Massachusetts headquartered Vertex Pharmaceuticals Inc.'s stock saw a drop of 1.41%, to close the day at $155.71. A total volume of 1.79 million shares was traded, which was above their three months average volume of 1.53 million shares. The Company's shares have advanced 7.53% in the last month, 1.83% in the previous three months, and 87.22% over the past year. The stock is trading 5.49% and 11.18% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Vertex Pharma, which discovers, develops, manufactures, and commercializes medicines for serious diseases, have an RSI of 60.68. 

On January 05th, 2018, research firm Bank of America/ Merrill upgraded the Company's stock rating from 'Neutral' to 'Buy'.

On January 10th, 2018, Vertex Pharma announced that the European Commission has granted extension of the Marketing Authorization for ORKAMBI® (lumacaftor/ivacaftor), the first medicine to treat the underlying cause of cystic fibrosis in people with two copies of the F508del mutation, to include children ages 6 through 11. Existing reimbursement agreements in countries, such as Ireland, will enable rapid access to ORKAMBI for these children. In other countries across the European Union, the Company will begin the country-by-country reimbursement process. Sign up today for the free research report on VRTX at:


Shares in Campbell, California headquartered VIVUS Inc. ended the 3.87% lower at $0.49. A total volume of 900,904 shares was traded, which was above their three months average volume of 728,520 shares. The stock is trading below its 50-day moving average by 17.99%. Furthermore, shares of VIVUS, which develops and commercializes therapies to address unmet medical needs in the US and the European Union, have an RSI of 36.11. 

On December 26th, 2017, VIVUS announced that it has reached agreement with Seth H. Z. Fischer pursuant to which he will step down as CEO and member of the Board of Directors, effective December 31st, 2017, and become a strategic consultant to the Company. The Board is working with an executive search firm to help identify Mr. Fischer's successor. Board member Thomas B. King will assume the role of interim CEO. Wall St. Equities' research coverage also includes the downloadable free report on VVUS at:


Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

WSE has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit


For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:Email: Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

Cision View original content:

SOURCE Wall St. Equities

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store